<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002300</url>
  </required_header>
  <id_info>
    <org_study_id>025A</org_study_id>
    <secondary_id>MEG8807</secondary_id>
    <nct_id>NCT00002300</nct_id>
  </id_info>
  <brief_title>A Study of Different Doses of Megestrol Acetate in Patients With AIDS Who Have Anorexia and Malnutrition</brief_title>
  <official_title>Phase II-III Randomized Double-Blind Study Comparing Megestrol Acetate at 100, 400, and 800 mg/Day, and Placebo in AIDS Patients With Anorexia and Cachexia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <brief_summary>
    <textblock>
      To compare the effects of megestrol acetate and placebo on body weight, anorexia, cachexia,&#xD;
      calorie intake, and nutritional parameters of patients with a confirmed diagnosis of AIDS. To&#xD;
      characterize dose response in relation to weight gain. To determine whether megestrol acetate&#xD;
      relative to placebo improves the perception of well-being among AIDS patients with cachexia.&#xD;
      To evaluate megestrol acetate's effect on immune function via skin test reactivity, T4/T8&#xD;
      ratio, and total lymphocytes.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <condition>Anorexia</condition>
  <condition>Cachexia</condition>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Megestrol acetate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Patient must have:&#xD;
&#xD;
          -  Confirmed diagnosis of AIDS (CDC definition).&#xD;
&#xD;
          -  Documented weight loss or anorexia.&#xD;
&#xD;
          -  Life expectancy = or &gt; 20 weeks.&#xD;
&#xD;
          -  The perception that the weight loss is a detriment to their well-being.&#xD;
&#xD;
          -  Ability to provide informed consent, read and write English.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Ganciclovir.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following are excluded:&#xD;
&#xD;
          -  Dementia or evidence of mental incompetence which would preclude compliance with the&#xD;
             protocol.&#xD;
&#xD;
          -  Diarrhea defined as 5 or more watery stools per day for at least 7 days.&#xD;
&#xD;
          -  Active uncontrolled systemic infections at the start of treatment.&#xD;
&#xD;
          -  (Patients may not be entered for at least 2 weeks after acute infection.) Clinical or&#xD;
             radiologic evidence of ascites or pleural effusions.&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Therapy designed to treat the underlying HIV infection or which may have a major&#xD;
             impact on appetite and/or weight gain.&#xD;
&#xD;
          -  Patients who have been started on zidovudine (AZT) within eight weeks. (Patients may&#xD;
             have been previously treated with AZT and failed or may currently be receiving AZT for&#xD;
             at least 8 weeks.)&#xD;
&#xD;
        Patients with the following are excluded:&#xD;
&#xD;
          -  Obstruction to food intake or impaired digestive/absorptive functions.&#xD;
&#xD;
          -  Contraindications to high-dose megestrol acetate (poorly controlled hypertension or&#xD;
             heart failure or deep vein thrombosis).&#xD;
&#xD;
          -  Inability to consent or be available for close follow-up.&#xD;
&#xD;
          -  Active systemic infections at the start of treatment.&#xD;
&#xD;
          -  Patients may not be started on any therapy designed to treat the underlying HIV&#xD;
             infection or which may have a major impact on appetite and/or weight gain.&#xD;
&#xD;
          -  Clinical or radiologic evidence of ascites or pleural effusions.&#xD;
&#xD;
          -  Patients may not be started on any therapy designed to treat the underlying HIV&#xD;
             infection or which may have a major impact on appetite and/or weight gain.&#xD;
&#xD;
          -  Patients who have been hospitalized or have suffered an exacerbation of their illness&#xD;
             associated with weight loss within the past 2 weeks are excluded.&#xD;
&#xD;
          -  Menstruating female patients are excluded.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Corticosteroids.&#xD;
&#xD;
          -  Anabolic steroids.&#xD;
&#xD;
          -  Marijuana.&#xD;
&#xD;
          -  Megestrol acetate.&#xD;
&#xD;
          -  Patients who have been started on zidovudine (AZT) within 8 weeks. (Patients may have&#xD;
             been previously treated with AZT and failed or may currently be receiving AZT for at&#xD;
             least 8 weeks.) History of substance abuse and questionable current and future&#xD;
             abstinence.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Birmingham Veterans Administration Med Ctr / Univ of Alabama</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr NS Tchekmedyian</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr Stephen J Gabin Jr</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90067</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eisenhower Med Ctr</name>
      <address>
        <city>Rancho Mirage</city>
        <state>California</state>
        <zip>92270</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Denver Public Health Dept</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>George Washington Univ Med Ctr</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Veterans Administration Med Ctr</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20422</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miami Veterans Administration Med Ctr</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33125</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern Univ Med School</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albany Med College / AIDS Treatment Ctr</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community Research Initiative on AIDS</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Vincent's Hosp and Med Ctr</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mem Sloan - Kettering Cancer Ctr</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Audie L Murphy Veterans Administration Hosp</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78284</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Strang P. The effect of megestrol acetate on anorexia, weight loss and cachexia in cancer and AIDS patients (review). Anticancer Res. 1997 Jan-Feb;17(1B):657-62.</citation>
    <PMID>9066597</PMID>
  </reference>
  <verification_date>October 2007</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>October 1, 2007</last_update_submitted>
  <last_update_submitted_qc>October 1, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 2, 2007</last_update_posted>
  <keyword>T-Lymphocytes</keyword>
  <keyword>Megestrol</keyword>
  <keyword>Dose-Response Relationship, Drug</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <keyword>Anorexia</keyword>
  <keyword>Cachexia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wasting Syndrome</mesh_term>
    <mesh_term>Anorexia</mesh_term>
    <mesh_term>Cachexia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Megestrol</mesh_term>
    <mesh_term>Megestrol Acetate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

